University Lab Technologies Files Patent for ARTHROLVE ULT(TM): University Lab Technologies Announced Today the Filing with the United States Patent Office for Its Blockbuster Arthroleve ULT(TM) Product for the Treatment of Arthritis

Share Article

Today's announcement marks the first of several patents the company has planned for the products in its product development pipeline.

The withdrawal of such blockbuster pharmaceutical products such as Vioxx(TM) and Celebrex(TM) has left millions of patients without a safe alternative for the relief of arthritic pain. We feel that this represents an incredible opportunity for the launch of our patent-pending, revolutionary Arthroleve product.

Dr Jarret Morrow, President and Chief Scientific Officer, was quoted as saying: "We believe that our patent submission represents a significant step forward in our mission of identifying, researching, and patenting formulations which are comprised of natural compounds that have clinically proven efficacy. Our patent filing represents a significant advancement in the preparation of pharmaceutical grade nutraceutical products which utilizes our advanced Slick Cap Technology(TM) to provide the optimal absorption mechanism for our key ingredients."

Arthritis represents the number one condition for which patients seek alternatives to prescription and over the counter pharmaceutical pain medication. Currently the marketplace for nutraceutical arthritis products is dominated by products which primarily contain glucosamine and chondroitin sulfate which take several weeks to work and provide limited pain relief. Conversely, our revolutionary Arthroleve(TM) product contains a synergistic combination of three ingredients which are clinically proven to provide significant relief of arthritic pain. Clinical studies have demonstrated that two ingredients in our formulation provide the same level of pain relief as Vioxx(TM) or Celebrex(TM), without any significant side effects.

The US joint pain market includes more than 43 million U.S. adults who suffer from arthritis and chronic pain. Approximately one-half of these individuals suffer from osteoarthritis. Other common rheumatic conditions include gout, fibromyalgia and rheumatoid arthritis. Arthritis affects people in all age groups including nearly 300,000 children. Arthritis accounts for 3% of all hospital intakes and nearly 4% of all ambulance services. Costs to the U.S. economy totals more than $86.2 billion annually. Statistics compiled by the National Center for Chronic Disease Prevention and Health Promotion say that Arthritis and other rheumatic conditions are the main cause of disability in the USA. By 2030, they estimate that 64.9 million Americans will have been formally diagnosed with an arthritic condition.

Dr. Morrow went on to say: "The withdrawal of such blockbuster pharmaceutical products such as Vioxx(TM) and Celebrex(TM) has left millions of patients without a safe alternative for the relief of arthritic pain. We feel that this represents an incredible opportunity for the launch of our patent-pending, revolutionary Arthroleve product."

About University Lab Technologies (http://www.universitylabtechnologies.com): Every year university labs around the globe identify, research and test natural compounds and formulations which have the potential to improve the quality of life of our lives.

Over 98% of these potentially life changing discoveries are never commercialized for the benefit of the public.

University Lab Technologies, in collaboration with universities worldwide, researches and identifies those compounds that have proven evidence based effects and have the greatest potential for improving our lives.

University Lab Technologies' mission is to deliver the latest advances and discoveries in natural compounds packaged in our unique patented formulations and delivered to satisfy the needs of consumers for the treatment of many common chronic ailments. http://www.universitylabtechnologies.com

Optimized by Newsforce

Share article on social media or email:

View article via:

Pdf Print

Contact Author

George Theodore
Visit website